Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of VIR-2218 in Adult Participants With Renal Impairment
NCT05844228Phase 1Completed
- Sponsor
- Vir Biotechnology
- Start
- Jun 2023
- Primary completion
- Mar 2025
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, open-label trial of elebsiran in hepatitis B (HBV) (2 cohorts), sponsored by Vir Biotechnology. Primary endpoints: Maximum Observed Plasma Concentration at 4 days, Area Under The Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration at 4 days and 4 more. Started Jun 2023; status: completed.
02
Drugs
elebsiran
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT05844228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05844228.